The Role of Vascular Endothelial Growth Factor +405 G/C Polymorphism and Albuminuria in Patients with Type 2 Diabetes Mellitus

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2011 May 13

PMID 21562766

Citations 9

Authors

Abdolrahim Nikzamir

Alireza Esteghamati

Amir Abbas Hammedian

Touraj Mahmoudi

Affiliations

Soon will be listed here.

Abstract

Observations on the association between the vascular endothelial growth factor (VEGF) gene polymorphism and nephropathy have been inconsistent, which might be due to ethnic and geographical variations. Furthermore, the relationship between +405 G/C polymorphism and albuminuria in the diabetic population has not been sufficiently studied. The aim of this study was to evaluate for the first time the possible association between +405 G/C polymorphism and albuminuria in an population from Tehran of Iran. A total of 255 consecutive patients with type 2 diabetes and microalbuminuria (Group A) and 235 patients with type 2 diabetes and normoalbuminuria (Group B) were included. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were used to detect the VEGF alleles. In univariate analysis, the groups were statistically similar in all variables except for HbA1c (8.53 ± 1.7 in Group A vs. 8.2 ± 1.73 in Group B; P = 0.034), 24-h urinary albumin (201.33 ± 84.8 in Group A vs. 22.88 ± 3.5 in Group B; P < 0.001), and the frequency of GG genotype (31% in Group A vs. 18.7% in Group B; P = 0.006). The GG genotype was the independent predictor of albuminuria [P = 0.014, OR = 1.771, 95% confidence interval (CI) = 1.124-2.790]. Our study showed that the G allele was not associated with albuminuria, but the GG genotype in the VEGF gene is independently associated with development of nephropathy in the our diabetic population.

Citing Articles

The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease.

Nouri S, Navari M, Shafiee R, Mahmoudi T, Rezamand G, Asadi A Rev Assoc Med Bras (1992). 2024; 70(7):e20231537.

PMID: 39045929 PMC: 11262324. DOI: 10.1590/1806-9282.20231537.

Insulin-like growth factor binding protein 3 promoter variant (rs2854744) is associated with nonalcoholic fatty liver disease.

Mahmoudi T, Nouri S, Zarei F, Najafabadi Z, Sanei M, Sayedsalehi S Arch Endocrinol Metab. 2023; 68:e230017.

PMID: 37948568 PMC: 10916839. DOI: 10.20945/2359-4292-2023-0017.

Vascular Endothelial Growth Factor Single Nucleotide Polymorphism +405 G/C (rs2010963) is associated with Levels, Infection Severity, and Amputation among South Indian Diabetic Foot Ulcer Patients.

Ganapathy P, Devanatha Desikan Sheshadri V, Sarkar R, Jones S, Gunasekaran K, Feysia T Evid Based Complement Alternat Med. 2023; 2023:2059426.

PMID: 37089713 PMC: 10118891. DOI: 10.1155/2023/2059426.

Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.

Moisuc D, Marinca M, Gafton B, Alexa-Stratulat T, Pavel-Tanasa M, Cianga P Curr Oncol. 2022; 29(6):3996-4011.

PMID: 35735428 PMC: 9221669. DOI: 10.3390/curroncol29060319.

Meta-Analysis and Bioinformatics Detection of Susceptibility Genes in Diabetic Nephropathy.

Tziastoudi M, Cholevas C, Theoharides T, Stefanidis I Int J Mol Sci. 2022; 23(1).

PMID: 35008447 PMC: 8744540. DOI: 10.3390/ijms23010020.

References

Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken R, Hugo C . Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006; 69(9):1654-61. DOI: 10.1038/sj.ki.5000294. View

Cha D, Kim N, Yoon J, Jo S, Cho W, Kim H . Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl. 2000; 77:S104-12. DOI: 10.1046/j.1523-1755.2000.07717.x. View

Ferrara N . Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest. 1995; 72(6):615-8. View

Schrijvers B, Flyvbjerg A, De Vriese A . The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004; 65(6):2003-17. DOI: 10.1111/j.1523-1755.2004.00621.x. View

Watson C, WEBB N, Bottomley M, Brenchley P . Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000; 12(8):1232-5. DOI: 10.1006/cyto.2000.0692. View

Tavakkoly-Bazzaz J, Amoli M, Pravica V, Chandrasecaran R, Boulton A, Larijani B . VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep. 2010; 37(7):3625-30. DOI: 10.1007/s11033-010-0013-6. View

Ferrara N . The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18(1):4-25. DOI: 10.1210/edrv.18.1.0287. View

Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F . Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med. 2000; 17(9):650-6. DOI: 10.1046/j.1464-5491.2000.00350.x. View

Tsilibary E . Microvascular basement membranes in diabetes mellitus. J Pathol. 2003; 200(4):537-46. DOI: 10.1002/path.1439. View

10.

Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H . Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis. 2005; 45(2):288-94. DOI: 10.1053/j.ajkd.2004.09.020. View

11.

Grone H . Angiogenesis and vascular endothelial growth factor (VEGF): is it relevant in renal patients?. Nephrol Dial Transplant. 1995; 10(6):761-3. View

12.

Flyvbjerg A, Dagnaes-Hansen F, De Vriese A, Schrijvers B, Tilton R, Rasch R . Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002; 51(10):3090-4. DOI: 10.2337/diabetes.51.10.3090. View

13.

Yang J, Hutchinson I, Shah T, Fang J, Min D . Gene polymorphism of vascular endothelial growth factor -1154 G>A is associated with hypertensive nephropathy in a Hispanic population. Mol Biol Rep. 2010; 38(4):2417-25. DOI: 10.1007/s11033-010-0376-8. View

14.

De Vriese A, Verbeuren T, Van de Voorde J, Lameire N, Vanhoutte P . Endothelial dysfunction in diabetes. Br J Pharmacol. 2000; 130(5):963-74. PMC: 1572156. DOI: 10.1038/sj.bjp.0703393. View

15.

Lenz T, Haak T, Malek J, Grone H, Geiger H, Gossmann J . Vascular endothelial growth factor in diabetic nephropathy. Kidney Blood Press Res. 2003; 26(5-6):338-43. DOI: 10.1159/000073940. View

16.

Wu L, Mayo L, DUNBAR J, Kessler K, Baerwald M, Jaffe E . Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem. 2000; 275(7):5096-103. DOI: 10.1074/jbc.275.7.5096. View

17.

Satchell S, Anderson K, Mathieson P . Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol. 2004; 15(3):566-74. DOI: 10.1097/01.asn.0000115397.22519.03. View

18.

Rutledge J, Ng K, Aung H, Wilson D . Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010; 6(6):361-70. DOI: 10.1038/nrneph.2010.59. View

19.

Trevisan R, Viberti G . Genetic factors in the development of diabetic nephropathy. J Lab Clin Med. 1995; 126(4):342-9. View

20.

Held P, Port F, Webb R, Wolfe R, Garcia J, Blagg C . The United States Renal Data System's 1991 annual data report: an introduction. Am J Kidney Dis. 1991; 18(5 Suppl 2):1-16. View